pSivida Corp

Board of Directors

Dr. James Barry

Dr. Barry is the Executive Vice President and Chief Operating Officer and a Director of InspireMD, a global medical device company focused on the development and commercialization of cardiovascular products. Dr. Barry has also been a Priincipal at Convergent Biomedical Group and served as President and CEO and a Director of Arsenal Medical and in various executive and managerial positions at Boston Scientific Corporation. Dr.Barry is also a Director of AgNovos Healthcare LLC. Dr.Barry's significant experience developing products, leading research and development teams and building successful businesses coupled with his expertise in advising clients in pharmaceutical, biotechnology and medical device industries,brings valuable technical expertise and commercial experience to pSivida.

Ms. Nancy Lurker
President & Chief Executive Officer

Nancy Lurker was appointed the Company's President & Chief Executive Officer in September 2016. Ms. Lurker has had broad ranging experience in the pharmaceutical industry and companies serving the pharmaceutical industry, including diverse senior leadership positions. From 2008 to 2015, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc., a NASDAQ-listed healthcare commercialization company. She successfully rebuilt PDI's contract sales business, launching numerous pharmaceutical products for multiple companies across diverse therapeutic areas, including ophthalmology, in advance of a sale of that business line to Publicis Healthcare Communications Group and then repositioned the company as the higher growth, higher margin molecular diagnostics business now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a multi-billion-dollar product portfolio covering cardiovascular, bone, pain, urology, respiratory, dermatology, biologics, neurology and metabolic therapeutic areas. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company, now part of IMS Health Holdings, Inc., where she substantially grew revenues and profitability. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory and women's health drugs, overseeing the worldwide launch of Detrol® and Detrol® LA and repositioning Ambien® for revenue growth. She also served as a member of Pharmacia's U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker serves as a member of the Board of Directors of the privately held Cancer Treatment Centers of America. Ms. Lurker previously served as a member of the Boards of Directors of Mallinckrodt Pharmaceuticals, plc (NYSE: MNK) and Auxilium Pharmaceuticals, Inc. (NASDAQ: ENDP). Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

Dr. Jay Duker

As chairman of ophthalmology for Tufts Medical Center, Dr. Duker is responsible for managing the hospital's clinical ophthalmology practice. His role as chairman of ophthalmology for Tufts University School of Medicine encompasses leading the academic mission of the school, educating medical students, residents, fellows and practicing eye-care providers in ophthalmology and conducting ophthalmic research. As the Director of the New England Eye Center, he leads an academic, multi-specialty eye care group with 35 ophthalmologists and nearly 200 employees.

In his clinical practice, Dr. Duker treats diseases of the posterior segment of the eye including age-related macular degeneration (AMD), diabetic retinopathy, posterior segment uveitis and retinal vascular diseases as well as rare retinal disorders. His principal research interests include retinal vascular disease, drug delivery to the eye, posterior uveitis and novel imaging techniques for the posterior segment. He has published nearly 200 peer-reviewed journal articles and authored four books on ophthalmology including a best-selling textbook. Dr. Duker serves on the editorial board of three ophthalmic journals. He is a graduate of Harvard University and Jefferson Medical College.

Dr. Duker is also a director of Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, and a co-founder and Director of Hemera Biosciences, a privately held company seeking to develop anti-complement gene based therapies for the treatment of dry and wet age related macular degeneration.

Kris Peterson
Dr. David J. Mazzo
Non Executive Chairman
David Mazzo

Dr. Mazzo is the Chief Executive Officer and a Director at Caladrius Biosciences. Prior to joining Caladrius (formerly NeoStem), Dr. Mazzo served as Chief Executive Officer and as Director of Regado Biosciences, a company focused on the development of novel anti-thrombotic drug systems for acute and sub-acute cardiovascular indications. Dr.Mazzo was also Chief Executive Officer and Director of Aeterna Zentaris, Inc. and Chief Executive Officer and Director at Chugai Pharma USA LLC,a biopharmaceutical company. Dr. Mazzo has also held senior management and executive positions in research and development and was a Director of the Essex Chimie European subsidiary at Schering-Plough Corporation. Dr.Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr.Mazzo received his M.S. in Chemistry and his Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst.

Mr. Douglas Godshall
Douglas Godshall

Doug Godshall is the Chief Executive Officer and a director of HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure. Mr. Godshall joined HeartWare in 2006 from Boston Scientific Corporation where he worked for 16 years. He held various executive and leadership positions at Boston Scientific, including President of the Vascular Surgery Division, a member of Boston Scientific's Operating Committee and had previously served as Vice President, Business Development where he oversaw more than 70 transactions including several strategic investments in the Ophthalmology arena.

Mr. Michael W. Rogers
Michael Rogers

Mr. Rogers is Chief Financial Officer of Acorda Therapeutics, Inc.,a biotechnology company focused on neurological disorders. Mr. Rogers brings significant financing, acquisition, investment banking, and partnering experience relating to pharmaceutical and biotech companies to the pSivida Board of Directors and is the Chairman of the pSivida Audit Committee. Prior to Acorda, Mr. Rogers served as Executive Vice-President and Chief Financial Officer of BG Medical Inc., a company focused on the development and commercialization of novel biomarker-based diagnostics and Executive Vice President, Chief Financial Officer and treasurer of Indevus Pharmaceuticals Inc.,a specialty pharmaceutical company, Executive Vice President and Chief Financial and Corporate Development Officer at Advanced Health Corporation, a health care information technology company,Vice President, Chief Financial Officer and Treasurer of AutoImmune, a biopharmaceutcal company, and Vice President, Investment Banking at Lehman Brothers, Inc. and at PaineWebber, Inc.

Search Investor Relations